written on 05.03.2014

Gilead hepatitis drug will earn $4 bn in 2014 alone


Gilead’s hepatitis C drug, Sovaldi, which was approved in December, is among the first of a new generation of treatments that can cure the disease faster and more reliably than previous drugs.
According to Bloomberg, the drug costs $84,000 for a 12-week course of treatment and is expected to produce $4.2 billion in revenue during 2014 and $8.1 billion in 2015.